Nanotech Investing Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
Nanotech Investing Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
Nanotech Investing Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
Nanotech Investing Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
Heliostar Metals to Present at the Precious Metals & Critical Minerals Virtual Investor Conference December 3
